Mepolizumab self-administration via autoinjector and prefilled syringe: the qualitative patient experience

Abstract

Background: Mepolizumab (Nucala®) is licensed for severe eosinophilic asthma (SEA). Autoinjector (AI) and prefilled syringe (PFS) have been developed to enable in-clinic and at-home self-administration which may improve patient treatment experience. Objectives: To summarise qualitative interview responses to understand the PTE with mepolizumab AI and PFS. Methods: Two studies (NCT03099096 & NCT03021304) in SEA patients evaluated the real-word use of mepolizumab (100mg SC) self-administered via AI and PFS. To capture the PTE of self-administering, qualitative exit interviews were completed in a subset of patients enrolled [AI (n=25) and PFS (n=7)]. Results: Table 1 summarises general experience responses and the most liked aspects of the mepolizumab AI and PFS. Conclusions: Ease of use and convenience were the most dominant responses describing the patients’ general experience and most liked aspects of mepolizumab AI. Ease of use and needle retractability were reported for the mepolizumab PFS. Funding: GSK [204959 (NCT03099096) and 205667 (NCT03021304)]